FDA Brief

Warning letters Drugs

FDA warning letter to

American Specialty Pharmacy, Inc. dba ASP Cares

High riskIssued Apr 5, 2021Posted Apr 27, 2021Office of Pharmaceutical Quality Operations, Division II

FDA warned outsourcing facility ASP Cares about sterile compounded drugs made under insanitary conditions and with CGMP violations.

What happened

FDA inspected ASP Cares' San Antonio, Texas facility from August 14 to August 23, 2018. The investigator found sterile drug products prepared under conditions that may have allowed contamination, plus CGMP violations, and said the firm's adverse event reporting procedures were inadequate. FDA also said the firm's compounded drugs lacked FDA-approved applications and adequate directions for use.

What FDA found

  1. FDA found sterile drug products prepared under insanitary conditions, including inadequate smoke studies and pressure monitoring and a crack in cleanroom caulking.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The firm failed to establish and follow written procedures to prevent microbiological contamination of sterile drugs, including validation of aseptic and sterilization processes.

    21 CFR 211.113(b)
  3. The firm failed to thoroughly investigate unexplained discrepancies or batch failures, whether or not the batch had been distributed.

    21 CFR 211.192
  4. The firm failed to test each batch for identity and strength of active ingredients before release.

    21 CFR 211.165(a)
  5. The firm's adverse event reporting procedure did not adequately define serious or unexpected adverse events.

    FDCA section 503B(b)(5) [21 U.S.C. § 353b(b)(5)]; 21 CFR 211.198
  6. The firm's compounded drugs lacked FDA-approved applications and adequate directions for use.

    FDCA sections 505(a), 301(d), 502(f)(1) [21 U.S.C. §§ 355(a), 331(d), 352(f)(1)]

What FDA wants

FDA asks the firm to notify the compliance office in writing within 15 working days of the specific steps taken to correct the violations and prevent recurrence, with supporting documents. If the firm cannot fully address the matter in that time, it must state the reason and the time needed.

Who should pay attention

  • hospitals and clinics that buy compounded sterile drugs
  • pharmacies and prescribers that use ASP Cares products
  • other outsourcing facilities with sterile compounding operations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk